ABSTRACT
Several clinical trials have reported that patients with cancer cachexia can benefit from n-3 polyunsaturated fatty acids (n-3 PUFAs) supplements; however, the results have been conflicting. This systematic review and meta-analysis aimed to evaluate the effect of n-3 PUFAs on cancer cachexia. A search of the PubMed, Embase, and Cochrane Library databases was performed to identify the included randomized controlled trials. Trials including patients with cancer cachexia who were administered a course of n-3 PUFAs were included. A meta-analysis on body weight, lean body weight, proinflammatory factors, quality of life, and median duration of survival was conducted. A total of 12 randomized controlled trials with 1184 patients were included. No effect on body weight (standard mean difference [SMD], 0.10; 95% CI, -0.06 to 0.26; P = .236), lean body weight (SMD, -0.17; 95% CI, -0.36 to 0.03, P = .095), or proinflammatory factors (interleukin-6: SMD, 0.31; 95% CI, -0.14 to 0.75; P = .18; tumor necrosis factor-α: SMD, -0.85; 95% CI, -2.39 to 0.69; P = .28) was observed. The use of n-3 PUFAs was associated with a significant improvement in quality of life (SMD, 0.70; 95% CI, 0.01-1.40; P = .048) and median duration of survival (median survival ratio, 1.10; 95% CI, 1.02-1.19; P = .014). For patients with cancer cachexia, our meta-analysis indicated that n-3 PUFAs improved quality of life and survival, but not body weight.
Subject(s)
Fatty Acids, Omega-3 , Neoplasms , Humans , Cachexia/drug therapy , Cachexia/etiology , Quality of Life , Fatty Acids, Omega-3/pharmacology , Fatty Acids, Omega-3/therapeutic use , Dietary Supplements , Neoplasms/complications , Neoplasms/drug therapy , Randomized Controlled Trials as TopicABSTRACT
Clinical trials have reported that a four-oil intravenous lipid emulsion (SMOFlipid) play a positive role in immune function, but showed inconsistent outcomes compared to other lipid emulsions. A systematic review and meta-analysis was conducted to evaluate the effect of SMOFlipid on liver function, triglycerides (TG), inflammatory markers, and clinical outcomes in hospitalized adults after short-term use compared to others. A search of the PubMed, Medline, Embase, China National Knowledge Infrastructure, and Wanfang databases was performed to identify the included randomized controlled trials. Trials with adults who were administrated a short-term course of SMOFlipid were included. A meta-analysis on liver function markers, TG, inflammatory markers, and clinical outcomes was conducted. A total of 18 randomized controlled trials with 1188 patients were included. Compared to other lipid emulsions, SMOFlipid was associated with a significant reduction in ALT, AST, γ-glutamyltransferase, total bilirubin, TG, C-reactive protein and length of hospital stay. No effect on serum interleukin-6 levels or adverse events were observed. For adult patients, our meta-analysis indicated that SMOFlipid may be beneficial to the liver and prone to prevent hyperlipidemia. The SMOFlipid also shortened length of hospital stay.
Subject(s)
Fat Emulsions, Intravenous/pharmacology , Fatty Acids, Omega-3/pharmacology , Fish Oils/pharmacology , Length of Stay , Liver/drug effects , Olive Oil/pharmacology , Parenteral Nutrition , Soybean Oil/pharmacology , Triglycerides/blood , Adult , Fat Emulsions, Intravenous/chemistry , Fat Emulsions, Intravenous/metabolism , Fat Emulsions, Intravenous/therapeutic use , Fatty Acids, Omega-3/blood , Fatty Acids, Omega-3/therapeutic use , Fish Oils/blood , Fish Oils/therapeutic use , Humans , Hyperlipidemias/prevention & control , Inflammation/prevention & control , Liver/metabolism , Olive Oil/therapeutic use , Plant Oils/metabolism , Plant Oils/pharmacology , Plant Oils/therapeutic use , Soybean Oil/blood , Soybean Oil/therapeutic use , Triglycerides/pharmacology , Triglycerides/therapeutic useABSTRACT
Surgery, radiotherapy, and chemotherapy are the main treatments for tongue cancer, but the nutritional status of patients is not considered. Nutritional treatment is often not standard or by experience. This article reports a patient with tongue cancer who underwent preoperative chemotherapy and postoperative nutrition treatment. The entire process of individualized and sequential nutrition therapy was adopted, and the nutritional status of the patient was significantly improved. This paper describes the methods of nutrition therapy and evaluation and discusses the treatment process and key points in combination with relevant literature.